Bayer HealthCare / Press

Bayer Submits an Application for Market Authorization of Recombinant Factor VIII Product as a Treatment of Hemophilia A in Japan

Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, as a treatment of hemophilia A. more      

In Focus

Healthcare News

Photos & Videos

  • Photos

    Photo galleries with topic-related images.
    more

  • TV Footage

    In this section you can find videos for editorial coverage. » more

    Videos

    The video section provides an overview of interesting videos for viewing. » more

Bayer HealthCare Links

RSS Feed
RSS Feed

http://press.healthcare.bayer.com/en/press/index.php

Copyright © Bayer HealthCare AG